Exicure, Inc. will issue 172,058 shares of common stock to GPCR Therapeutics to settle a $1 million clinical milestone payment triggered by the completion of a Phase 2 trial for Burixafor. The shares, valued at $5.81 each, will be issued in August 2026, preserving Exicure's cash and financial flexibility. This milestone payment follows the submission of the Clinical Study Report to the FDA in January 2026. Exicure is currently exploring strategic alternatives after restructuring and aims to update the market once the issuance is complete.
Halper Sadeh LLC is investigating whether officers and directors of iRhythm Technologies breached their fiduciary duties to shareholders. Long-term iRhythm stockholders may seek reforms, financial incentives, or other relief if misconduct is found. T...
Bitcoin hovered close to $63,000 with minor fluctuations, as traders watched critical support at $62,200 and resistance near $63,400. Market experts predict volatile trading until Bitcoin decisively breaks above $65,000, which could trigger stronger ...
Cybercriminals exploited a critical vulnerability in macOS Screen Sharing to gain root access and deploy Monero mining malware on exposed Macs. The Dutch National Cyber Security Centre confirmed active attacks targeting systems with port 5900 open on...
Halper Sadeh LLC is investigating whether MongoDB's officers and directors breached their fiduciary duties to shareholders. Long-term MongoDB stockholders may be eligible to seek corporate governance reforms, financial incentives, or other relief. Th...
Halper Sadeh LLC is investigating whether certain officers and directors of WEBTOON Entertainment Inc. violated their fiduciary duties to shareholders. Long-term WEBTOON stockholders may seek corporate governance reforms, financial incentives, or oth...
